Based on the IC50 obtained for NHC-Pt-I2 after 1 h exposure of BRAF-m or BRAF-wt skin or lymph node metastatic cutaneous melanoma cells, we believe that NHC-Pt-I2-containing chemotherapies delivered at a low dose would be an interesting approach. The gene discussed is BRAF; the disease is cutaneous melanoma.